BioAge Labs reports Q1 EPS (52c), consensus (63c)

Reports Q1 revenue $2.77M, consensus $1.08M. “The positive topline Phase 1 data we reported for BGE-102 in April reinforce our conviction that we have a potential best-in-class NLRP3 inhibitor: a well-tolerated, once-daily oral therapy that could deliver the anti-inflammatory efficacy of injectables,” said Kristen Fortney, CEO and co-founder of BioAge. “Our focus now is execution. We plan to initiate two BGE-102 proof-of-concept trials by mid-2026 – a Phase 2 dose-ranging trial in cardiovascular risk, and a Phase 1b/2a trial in diabetic macular edema – advancing BGE-102 as a potential ‘pipeline in a pill’ across cardiometabolic and ocular diseases. With the $132.3 million we raised in our upsized follow-on offering earlier this year, we have the capital to drive both programs through key milestones.”